Gross O - Search Results

1

[Update on: COVID-19 and the kidney - clinic].

Böckhaus J, Plüß M, Tampe B, Gross O. Böckhaus J, et al. Among authors: gross o. Nephrologe. 2021;16(5):314-318. doi: 10.1007/s11560-021-00530-1. Epub 2021 Aug 10. Nephrologe. 2021. PMID: 34394758 Free PMC article. German. No abstract available.

2

Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.

Zhang Y, Böckhaus J, Wang F, Wang S, Rubel D, Gross O, Ding J. Zhang Y, et al. Among authors: gross o. Pediatr Nephrol. 2021 Sep;36(9):2719-2730. doi: 10.1007/s00467-021-05040-9. Epub 2021 Mar 27. Pediatr Nephrol. 2021. PMID: 33772369 Free PMC article.

3

Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study.

Gross O, Moerer O, Rauen T, Böckhaus J, Hoxha E, Jörres A, Kamm M, Elfanish A, Windisch W, Dreher M, Floege J, Kluge S, Schmidt-Lauber C, Turner JE, Huber S, Addo MM, Scheithauer S, Friede T, Braun GS, Huber TB, Blaschke S. Gross O, et al. J Clin Med. 2021 Jul 9;10(14):3049. doi: 10.3390/jcm10143049. J Clin Med. 2021. PMID: 34300217 Free PMC article.

4

[COVID-19 and the kidneys-Clinical aspects].

Gross O. Gross O. Nephrologe. 2021;16(1):26-32. doi: 10.1007/s11560-020-00470-2. Epub 2020 Dec 11. Nephrologe. 2021. PMID: 33343739 Free PMC article. Review. German.

5

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.

Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C; Alport Syndrome Research Collaborative. Kashtan CE, et al. Among authors: gross o. Pediatr Nephrol. 2013 Jan;28(1):5-11. doi: 10.1007/s00467-012-2138-4. Epub 2012 Mar 30. Pediatr Nephrol. 2013. PMID: 22461141 Free PMC article.

6

Alport syndrome--insights from basic and clinical research.

Kruegel J, Rubel D, Gross O. Kruegel J, et al. Among authors: gross o. Nat Rev Nephrol. 2013 Mar;9(3):170-8. doi: 10.1038/nrneph.2012.259. Epub 2012 Nov 20. Nat Rev Nephrol. 2013. PMID: 23165304 Review.

7

Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis.

Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA. Gross O, et al. Am J Hypertens. 2011 Mar;24(3):355-61. doi: 10.1038/ajh.2010.231. Epub 2010 Dec 2. Am J Hypertens. 2011. PMID: 21127470

8

Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.

Rubel D, Stock J, Ciner A, Hiller H, Girgert R, Müller GA, Gross O. Rubel D, et al. Among authors: gross o. Nephrol Dial Transplant. 2014 May;29(5):1012-9. doi: 10.1093/ndt/gft434. Epub 2013 Nov 5. Nephrol Dial Transplant. 2014. PMID: 24198271

9

Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport Syndrome.

Muckova P, Wendler S, Rubel D, Büchler R, Alert M, Gross O, Rhode H. Muckova P, et al. Among authors: gross o. J Proteome Res. 2015 Dec 4;14(12):5202-14. doi: 10.1021/acs.jproteome.5b00814. Epub 2015 Nov 3. J Proteome Res. 2015. PMID: 26487288

10

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.

Stock J, Kuenanz J, Glonke N, Sonntag J, Frese J, Tönshoff B, Höcker B, Hoppe B, Feldkötter M, Pape L, Lerch C, Wygoda S, Weber M, Müller GA, Gross O. Stock J, et al. Among authors: gross o. Pediatr Nephrol. 2017 Jan;32(1):131-137. doi: 10.1007/s00467-016-3452-z. Epub 2016 Jul 11. Pediatr Nephrol. 2017. PMID: 27402170

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page